Evolocumab (German Wikipedia)

Analysis of information sources in references of the Wikipedia article "Evolocumab" in German language version.

refsWebsite

Global rank German rank

2^nd place

3^rd place

low place

4^th place

7^th place

68^th place

29^th place

1^st place

14^th place

31^st place

5,225^th place

2,461^st place

amgen.com

J. M. Reichert: Antibodies to watch in 2014. In: mAbs. Band 6, Nr. 1, 2014, S. 5–14, doi:10.4161/mabs.27333, PMID 24284914.
Evan A. Stein u. a.: Effect of a Monoclonal Antibody to PCSK9 on LDL Cholesterol. In: New England Journal of Medicine. Band 366, Nr. 12, 2012, S. 1108–1118, doi:10.1056/NEJMoa1105803, PMID 22435370.
M. S. Sabatine: Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease. In: New England Journal of Medicine. Band 376, 2017, S. 1713–1722, doi:10.1056/NEJMoa1615664.
Marc S. Sabatine, Robert P. Giugliano, Stephen D. Wiviott, Frederick J. Raal, Dirk J. Blom, Jennifer Robinson, Christie M. Ballantyne, Ransi Somaratne, Jason Legg, Scott M. Wasserman, Robert Scott, Michael J. Koren, Evan A. Stein: Efficacy and Safety of Evolocumab in Reducing Lipids and Cardiovascular Events. In: New England Journal of Medicine. Band 372, Nr. 16, 2015, S. 1500–1509, doi:10.1056/NEJMoa1500858.

J. M. Reichert: Antibodies to watch in 2014. In: mAbs. Band 6, Nr. 1, 2014, S. 5–14, doi:10.4161/mabs.27333, PMID 24284914.
Evan A. Stein u. a.: Effect of a Monoclonal Antibody to PCSK9 on LDL Cholesterol. In: New England Journal of Medicine. Band 366, Nr. 12, 2012, S. 1108–1118, doi:10.1056/NEJMoa1105803, PMID 22435370.